173 related articles for article (PubMed ID: 18463528)
1. Comment of article by Matsumoto Y.
Campa C; D'Angelo S; Incorvaia C
Retina; 2008 May; 28(5):782; author reply 782-3. PubMed ID: 18463528
[No Abstract] [Full Text] [Related]
2. Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease.
Matsumoto Y; Freund KB; Peiretti E; Cooney MJ; Ferrara DC; Yannuzzi LA
Retina; 2007; 27(4):426-31. PubMed ID: 17420693
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab for branch retinal vein occlusion.
Spandau U; Wickenhäuser A; Rensch F; Jonas J
Acta Ophthalmol Scand; 2007 Feb; 85(1):118-9. PubMed ID: 17244225
[No Abstract] [Full Text] [Related]
4. Bevacizumab and macular edema.
Kumar A
Ophthalmology; 2008 Mar; 115(3):585. PubMed ID: 18319106
[No Abstract] [Full Text] [Related]
5. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
[TBL] [Abstract][Full Text] [Related]
6. Retinal sensitivity after intravitreal injection of bevacizumab for the treatment of macular edema secondary to retinal vein occlusion.
Yamaike N; Tsujikawa A; Sakamoto A; Ota M; Kotera Y; Miyamoto K; Kita M; Yoshimura N
Retina; 2009 Jun; 29(6):757-67. PubMed ID: 19289982
[TBL] [Abstract][Full Text] [Related]
7. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion.
Rabena MD; Pieramici DJ; Castellarin AA; Nasir MA; Avery RL
Retina; 2007; 27(4):419-25. PubMed ID: 17420692
[TBL] [Abstract][Full Text] [Related]
9. Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes.
Campochiaro PA; Hafiz G; Channa R; Shah SM; Nguyen QD; Ying H; Do DV; Zimmer-Galler I; Solomon SD; Sung JU; Syed B
Ophthalmology; 2010 Dec; 117(12):2387-2394.e1-5. PubMed ID: 20630595
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion.
Lim JW
Ophthalmologica; 2011; 225(3):150-4. PubMed ID: 21150231
[TBL] [Abstract][Full Text] [Related]
11. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion.
Pai SA; Shetty R; Vijayan PB; Venkatasubramaniam G; Yadav NK; Shetty BK; Babu RB; Narayana KM
Am J Ophthalmol; 2007 Apr; 143(4):601-6. PubMed ID: 17306753
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial.
Priglinger SG; Wolf AH; Kreutzer TC; Kook D; Hofer A; Strauss RW; Alge CS; Kunze C; Haritoglou C; Kampik A
Retina; 2007 Oct; 27(8):1004-12. PubMed ID: 18040236
[TBL] [Abstract][Full Text] [Related]
13. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion.
Rensch F; Jonas JB; Spandau UH
Acta Ophthalmol; 2009 Feb; 87(1):77-81. PubMed ID: 18937800
[TBL] [Abstract][Full Text] [Related]
14. Treatment of branch retinal vein occlusion induced macular edema with bevacizumab.
Abegg M; Tappeiner C; Wolf-Schnurrbusch U; Barthelmes D; Wolf S; Fleischhauer J
BMC Ophthalmol; 2008 Sep; 8():18. PubMed ID: 18823536
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion.
Parveen S; Narayanan R; Sambhav K; Bhatia K
Retina; 2010 Sep; 30(8):1324-5; author reply 1325. PubMed ID: 20827152
[No Abstract] [Full Text] [Related]
16. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab treatment of macular oedema due to central retinal vein occlusion.
Spandau UH; Ihloff AK; Jonas JB
Acta Ophthalmol Scand; 2006 Aug; 84(4):555-6. PubMed ID: 16879582
[No Abstract] [Full Text] [Related]
18. Combination therapy for retinal vein occlusion.
Shimura M; Yasuda K; Nakazawa T; Takeshita T; Shiono T; Sakamoto T
Ophthalmology; 2010 Sep; 117(9):1858, 1858.e1-3. PubMed ID: 20816249
[No Abstract] [Full Text] [Related]
19. Intravitreal bevacizumab (Avastin) for the treatment of cystoid macular edema in Behçet disease.
Mirshahi A; Namavari A; Djalilian A; Moharamzad Y; Chams H
Ocul Immunol Inflamm; 2009; 17(1):59-64. PubMed ID: 19294576
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
